(Total Views: 482)
Posted On: 10/26/2023 2:36:19 PM
Post# of 153903
Merck announced their third-quarter results today. For those who like to think about what sales of Leronlimab (and stock price) might be down the road, this was their announcement for Keytruda:
https://www.cnbc.com/2023/10/26/merck-mrk-q3-...-2023.html
That equates to about $25B/year for just one indication.
Here is another excerpt:
Surely they have been kicking the tires on Leronlimab (or will do so after hold is removed?).
Quote:
Merck’s popular antibody treatment Keytruda, which is used to treat several types of cancer, booked $6.34 billion in revenue, up 17% from the year-earlier quarter.
https://www.cnbc.com/2023/10/26/merck-mrk-q3-...-2023.html
That equates to about $25B/year for just one indication.
Here is another excerpt:
Quote:
The company has been under pressure to reduce its dependence on Keytruda, which is slated to lose patent protection in 2028. But Merck is trying to defend its patent edge over Keytruda by developing new formulations of the drug, such as a version that can be injected under the skin.
Surely they have been kicking the tires on Leronlimab (or will do so after hold is removed?).
(6)
(0)
